Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: GU tumours, prostate

1357O - Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Date

11 Sep 2022

Session

Proffered Paper session: GU tumours, prostate

Topics

Clinical Research;  Therapy

Tumour Site

Prostate Cancer

Presenters

Fred Saad

Citation

Annals of Oncology (2022) 33 (suppl_7): S616-S652. 10.1016/annonc/annonc1070

Authors

F. Saad1, A.J. Armstrong2, A. Thiery-Vuillemin3, M. Oya4, N.D. Shore5, G. Procopio6, C. Arslan7, N. Mehra8, F. Parnis9, E. Brown10, F. Constans Schlurmann11, J.Y. Joung12, M. Sugimoto13, O. Sartor14, Y. Liu15, C.H. Poehlein16, C. Desai17, P.M.D. Del Rosario17, N. Clarke18

Author affiliations

  • 1 Department Of Urology, Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, H2X 3J4 - Montreal/CA
  • 2 Department Of Medicine, Duke Cancer Institute Center, Durham/US
  • 3 Medical Oncology Department, CHRU Besançon Hôpital J.Minjoz, 25030 - Besancon/FR
  • 4 Department Of Urology, Keio University School of Medicine, Tokyo/JP
  • 5 Surgery And Oncology, Carolina Urologic Research Center, Myrtle Beach/US
  • 6 Medical Oncology Department, Istituto Nazionale Per Cura Tumori Milano, 20133 - Milan/IT
  • 7 Medical Oncology Department, Izmir Economy University Medical Park Hospital, Karsiyaka/TR
  • 8 Medical Oncology Department, Radboud Universitair Medisch Centrum, Nijmegen/NL
  • 9 Medical Oncology Department, Ashford Cancer Centre Research, 5037 - Kurralta Park/AU
  • 10 Medical Oncology Department, University Hospital Southampton, SO16 6YD - Southampton/GB
  • 11 Medical Oncology Department, Centre Hospitalier de Cornouaille, Quimper/FR
  • 12 Center For Urological Cancer, National Cancer Center, Goyang-si/KR
  • 13 Urology Department, Kagawa University Hospital, Kagawa/JP
  • 14 Hematology/oncology Department, Tulane Cancer Center, 70112 - New Orleans/US
  • 15 Precision Medicine, Oncology R&d, Astrazeneca, CB2 0AA - Cambridge/GB
  • 16 Clinical Research, Merck & Co., Inc., Rahway/US
  • 17 Global Medicines Development, Oncology R&d, AstraZeneca, Cambridge/GB
  • 18 Department Of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester/GB
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1357O

Background

At the primary analysis of PROpel (NCT03732820; data cut-off [DCO]: 30/07/21), abi + ola significantly prolonged radiographic progression-free survival (rPFS) vs pbo + abi in 1L mCRPC (HR 0.66, 95% CI 0.54–0.81; P<0.0001). Overall survival (OS) trended towards a benefit with abi + ola vs abi + pbo (28.6% maturity; HR 0.86, 95% CI 0.66–1.12). We report biomarker analysis from the primary analysis and updated overall survival and safety data from a planned OS interim analysis (DCO2).

Methods

PROpel is a double-blind, pbo-controlled trial. 796 pts were randomized 1:1 to ola (300 mg twice daily [bid]) or pbo, and abi (1000 mg once daily) + prednisone or prednisolone (5 mg bid), irrespective of homologous recombination repair gene mutation (HRRm) status. The primary endpoint was rPFS by investigator assessment. OS was a key secondary endpoint. Aggregated results from tumour tissue (FoundationOne®CDx) and circulating tumour DNA (FoundationOne®Liquid CDx) tests were used to classify pts HRRm status.

Results

Pts with HRRm, including BRCAm, were balanced between treatment arms and rPFS favoured abi + ola for all biomarker subgroups, including pts with non-HRRm, HRRm and BRCAm status (HR 0.76, 0.50 and 0.23 respectively; Table). Sensitivity analysis of rPFS by blinded independent central review was consistent. At DCO2 (14/03/22) rPFS was consistent with the primary analysis (25.0 vs 16.4 months; HR 0.67, 95% CI 0.56–0.81). A trend towards improved OS with abi + ola vs abi + pbo continued (maturity 40%; HR 0.83; 95% CI 0.66–1.03). Safety and tolerability results remained stable.

Conclusions

Meaningful rPFS improvement of ≥5 months was observed with abi + ola vs abi + pbo in all assessed biomarker subgroups. Updated results show a continuing trend towards improved OS and support a superior clinical benefit with abi + ola vs abi + pbo as 1L therapy for pts with mCRPC. Table: 1357O

Biomarker subgroup analyses

Abi + ola (N=399) Abi + pbo (N=397) HR (95% CI)
n Events (%) Median rPFS (months) n Events (%) Median rPFS (months)
ITT population 399 168 (42) 24.8 397 226 (57) 16.6 0.66 (0.54–0.81)
Non-HRRm 279 119 (43) 24.1 273 149 (55) 19.0 0.76 (0.60–0.97)
HRRm* 111 43 (39) NR 115 73 (64) 13.9 0.50 (0.34‒0.73)
Non-BRCAm 343 148 (43) 24.1 350 194 (55) 19.0 0.76 (0.61‒0.94)
BRCAm 47 14 (30) NR 38 28 (74) 8.4 0.23 (0.12‒0.43)

*Genes assessed were ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L BRCA1 and/or BRCA2ITT, intention-to-treat, NR, not reachedHRRm unknown pts (n=18) were excluded from the analysis.

Clinical trial identification

NCT03732820.

Editorial acknowledgement

Medical writing support was provided by Kirstin Spence, PhD, at Mudskipper Business Ltd., funded by AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Disclosure

F. Saad: Financial Interests, Personal, Other, Honoraria: AbbVie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Financial Interests, Personal, Advisory Role: AbbVie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Financial Interests, Institutional, Funding: Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst). A.J. Armstrong: Financial Interests, Personal, Advisory Role: Janssen; Novartis; Myovant Sciences; Bayer; Exelixis; Dendreon; Merck; GoodRx; AstraZeneca; FORMA Therapeutics; Astellas Scientific and Medical Affairs Inc.; Pfizer; Bristol Myers Squibb; Exelixis; Financial Interests, Institutional, Funding: Gilead Sciences (Inst); Roche/Genentech (Inst); Bristol Myers Squibb (Inst); AstraZeneca (Inst); FORMA Therapeutics (Inst); Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Pfizer (Inst); Amgen (Inst); Novartis (Inst); Janssen; Financial Interests, Institutional, Royalties: Circulating Tumor Cell Novel Capture Technology (Inst); Financial Interests, Personal, Other, Travel/accommodation: Astellas Scientific and Medical Affairs Inc. A. Thiery-Vuillemin: Financial Interests, Personal, Advisory Board, & public speaking: Pfizer, AstraZeneca, Janssen, Ipsen, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Sanofi, Novartis, Roche/Genentech, MSD, Astellas Pharma; Financial Interests, Institutional, Funding: Pfizer, Ipsen, Bayer; Financial Interests, Institutional, Invited Speaker: Pfizer, AstraZeneca, Sanofi, JNJ, Novartis, Ipsen, Roche, BMS, MSD, Astellas Pharma, excelixis, UNICANCER / GETUG, Incyte; Financial Interests, Invited Speaker: AstraZeneca, Novartis, BMS; Non-Financial Interests, Member: ASCO, GETUG; Other, Travel, Accommodations: Roche, MSD, JNJ, BMS, AstraZeneca, Pfizer, Astellas Pharma, Ipsen. M. Oya: Financial Interests, Personal, Other, Honoraria: Ayer; Bristol Myers Squibb; Novartis; Ono Pharmaceutical; Pfizer; AstraZeneca, Astellas and Takeda; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Funding: Novartis; Pfizer. N.D. Shore: Financial Interests, Personal, Advisory Role, Consultant/Independent Contractor: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, Clarity, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, Lantheus, Lilly, MDxhealth, Merck, Myovant. G. Procopio: Financial Interests, Personal, Advisory Board, consultant fees: Astellas, AstraZeneca, Bayer, BMS, Janssen, Ipsen, Merck, MSD, Novartis, Pfizer; Financial Interests, Institutional, Research Grant, research Funding for No Profit Clinical Trial: Ipsen. C. Arslan: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Bristol Myers Squib, Janssen, Novartis, Pfizer, Teva; Financial Interests, Personal, Speaker’s Bureau: Amgen, AstraZeneca, Bristol Myers Squib, Janssen, Novartis, Pfizer, Teva; Financial Interests, Institutional, Funding: Amgen (Inst), AstraZeneca (Inst), Bristol Myers Squib (Inst), Incyte (Inst), Janssen (Inst), Henlius (Inst), Merck (Inst), Yuhan (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst); Financial Interests, Personal, Other, Travel: Amgen, Astra Zeneca, Bristol Myers Squib, Janssen, Merck, Novartis, Pfizer, Teva. N. Mehra: Financial Interests, Personal, Advisory Board: Pfizer, Roche, MSD, AstraZeneca, Astellas, JNJ; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Funding: Astellas, Pfizer; Financial Interests, Personal and Institutional, Funding: Janssen; Financial Interests, Institutional, Invited Speaker: BMS, Janssen, BMS; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Non-Financial Interests, Leadership Role, Head of the Prostate Cancer Working group: Dutch Uro-Oncology Study Group; Non-Financial Interests, Principal Investigator, Co-PI: Prospective Bladder Cancer Infrastructure (Netherlands); Non-Financial Interests, Leadership Role: Castration-resistant Prostate Cancer Registry. F. Parnis: Financial Interests, Personal, Advisory Role: Ipsen; Janssen Oncology; Merck Serono. F. Constans Schlurmann: Financial Interests, Personal, Other, Honoraria: AAA, AstraZeneca; Astellas; Bayer; BMS; Janssen; MSD, Pfizer; Financial Interests, Personal, Advisory Role: AAA, AstraZeneca; Astellas; Bayer; BMS; Janssen; MSD, Pfizer; Financial Interests, Personal, Other, Travel: AAA, AstraZeneca; Astellas; Bayer; BMS; Janssen; MSD, Pfizer. M. Sugimoto: Financial Interests, Personal and Institutional, Funding, Honoraria; travel expenses: Janssen Pharmaceutical, AstraZeneca; Financial Interests, Personal, Other, Honoraria: Takeda Pharmaceutical; Financial Interests, Personal and Institutional, Funding, Honoraria, travel, accommodation and expenses: Astellas Pharma; Financial Interests, Personal, Funding, Travel expenses: BMS; Financial Interests, Personal and Institutional, Funding, Travel expenses: MSD; Financial Interests, Institutional, Funding: Pfizer; Financial Interests, Personal, Other, Travel expenses: Bayer. O. Sartor: Financial Interests, Personal, Advisory Role: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janss; Financial Interests, Personal, Research Grant: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio. Y. Liu, C. Desai, P.M.D. Del Rosario: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. Poehlein, C.H. Poehlein: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc. N. Clarke: Financial Interests, Personal, Other, Honoraria: Janssen; Bayer; AstraZeneca; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Other, Consulting: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.